The U.S. Food and Drug Administration has granted Carlsbad’s Greenwich Biosciences and its parent company priority review of a cannabis drug.
Greenwich Biosciences, a subsidiary of United Kingdom-based GW Pharmaceuticals, developed epidolex, a treatment for seizures in two rare, severe childhood-onset epilepsy disorders. The new designation speeds up the review process, and marks the FDA’s first time reviewing a cannabis plant-derived medicine, according to Greenwich Biosciences.
Epidolex is a cannabidiol, which lacks the psychotropic effects of THC (tetrahydrocannabidinol), found in many cannabis products. Previously, the drug received orphan drug and fast track designations.
Earlier this year, Greenwich BioSciences, quadrupled its office space size, moving into a 21,000-square-foot space in Carlsbad. Last March, the company stated it plans to increase its local workforce from 25 to 100 people within the next 12-18 months.